0026-895X/07/7206-1402–1405$20.00
MOLECULAR PHARMACOLOGY
Vol. 72, No. 6
42077/3281937
Mol Pharmacol 72:1402–1405, 2007
Printed in U.S.A.

MOL PHARM

PERSPECTIVE

Go It Alone No More—P2X7 Joins the Society of Heteromeric ATP-Gated Receptor Channels

George R. Dubyak

Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio

Received September 24, 2007; accepted September 25, 2007

ABSTRACT

P2X receptors (P2XR) function as ATP-gated nonselective ion channels permeable to Na^+, K^+, and Ca^{2+}, and they are expressed in a wide range of excitable, epithelial/endothelial, and immune effector cell types. The channels are trimeric complexes composed of protein subunits encoded by seven different P2XR genes expressed in mammalian and other vertebrate genomes. Current genetic, biochemical, and/or physiological evidence indicates that the extended family of functional P2X receptors includes six homomeric channels composed of P2X1, P2X2, P2X3, P2X4, P2X5, or P2X7 subunits and six heteromeric channels that involve subunit pairings of P2X1/P2X2, P2X1/P2X4, P2X1/P2X5, P2X2/P2X3, P2X2/P2X6, or P2X4/P2X6. Thus, all P2XR subtypes—with the salient exception of P2X7R—have previously been implicated in the assembly of heteromeric ATP-gated ion channels that can comprise unique pharmacological targets in different tissues. The assumed "go-it alone" function of the P2X7R has important implications because agents that target this particular receptor have been proposed as useful therapeutics in various autoinflammatory diseases or amelioration of inflammatory pain. However, this assumption and the interpretations based on it now require reevaluation in light of a new report in this issue of *Molecular Pharmacology* (p. 1447) that provides convincing biochemical and electrophysiological evidence for the existence of P2X4/P2X7 heteromeric receptors.

P2X receptors (P2XR) function as ATP-gated nonselective ion channels permeable to Na^+, K^+, and Ca^{2+} (for review, see North, 2002; Khakh and North, 2006). Most P2XR are expressed in excitable or epithelial/endothelial tissues; their ability to act as direct conduits for Ca^{2+} influx or indirect activators of voltage-gated Ca^{2+} channels underlies their multiple roles in Ca^{2+}-based signaling responses in those tissues. The channels are oligomeric complexes composed of protein subunits encoded by seven different P2XR genes (named P2X1 through P2X7 based on the order of cloning) expressed in mammalian and other vertebrate genomes. The seven P2XR subunits share a similar structure comprising two transmembrane segments, an extracellular loop containing 10 similarly spaced cysteines and glycosylation sites, and intracellular amino and carboxyl termini. All functional P2XR subtypes display a very high selectivity for ATP over other physiological nucleotides and—with the notable exception of P2X7R—micromolar affinity for ATP (EC_{50}, 1–10 μM) (North and Surprenant, 2000). It is remarkable that activation of the P2X7R requires near-millimolar concentrations of ATP ($EC_{50} \approx 300$ μM). This feature of P2X7R—together with its high expression and multiple roles in immune and inflammatory effector cells—has marked the P2X7R for particular attention by immunologists, electrophysiologists, and neuroscientists; reviewed in (Ferrari et al., 2006). Detailed understanding of the molecular pharmacology of these receptor channels is important because agents that target P2X7R have been proposed as useful therapeutics in various autoinflammatory diseases or amelioration of inflammatory pain (Chessell et al., 2005; Honore et al., 2006; Donnelly-Roberts and Jarvis, 2007).

Functional channels composed of P2XR subunits self-assemble during in vivo translation into stable, detergent-resistant trimeric complexes that traffic to the plasma membrane (Torres et al., 1999). When expressed separately as heterologous products in *Xenopus laevis* oocytes or HEK293

Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.107.042077.
Please see the related article on page 1447.

ABBREVIATIONS: P2XR, P2X receptor; ROCK, Rho-effector kinase.

cells, each P2XR subtype (with the exception of P2X6) can form homomeric ATP-gated ion channels. However, multiple studies have revealed that coexpression of various pairs of P2XR subtypes can yield heteromeric channels with function and pharmacology distinct from the homomeric trimers composed of either partner in the pair (North, 2002). The unique properties of natively expressed ATP-gated channels in certain tissues can be only explained by the heteromeric pairing of particular P2XR subtypes. Current genetic, biochemical, and/or physiological evidence indicates that the extended family of functional P2X receptors includes six homomeric channels composed of P2X1, P2X2, P2X3, P2X4, P2X5, or P2X7 subunits (North, 2002) and six heteromeric channels that involve subunit pairings of P2X1/P2X2 (Brown et al., 2002), P2X1/P2X4 (Nicke et al., 2005), P2X1/P2X5 (Torres et al., 1998), P2X2/P2X3 (Lewis et al., 1995), P2X2/P2X6 (King et al., 2000), or P2X4/P2X6 (Lê et al., 1998). Thus, all P2XR subtypes—with the salient exception of P2X7R—have previously been implicated in the assembly of heteromeric ATP-gated ion channels that can comprise unique pharmacological targets in different tissues.

The apparent "go it alone" status of P2X7R has been a fundamental assumption in: 1) analyses of the channel functions and membrane trafficking characteristics of engineered or naturally occurring P2X7 mutant or polymorphic variants; 2) interpretation of the various physiological and pathological phenotypes in P2X7R-knockout mice; and 3) the design/use of pharmacological agents that activate, antagonize, or allosterically modulate P2X7R. However, this assumption and the interpretations based on it now require re-evaluation in light of a report in this issue of *Molecular Pharmacology* by Guo et al. (2007), who provide convincing biochemical and electrophysiological evidence for the existence of P2X4/P2X7 heteromeric receptors. The supporting data include the usual immunoprecipitation of protein complexes containing both subunits in detergent extracts from cotransfected HEK293 cells and—very significantly—from primary murine macrophages that natively express both P2X7R and P2X4R. A particularly elegant series of studies used a point mutant (S341W) of P2X4 previously shown to assemble into homomeric complexes that traffic to the plasma membrane but lack ATP-gated channel activity (Silberberg et al., 2005). Coexpression of P2X4-S341W with P2X7 yielded ATP-gated ion currents that were markedly potentiated by ivermectin. The latter is a macrocyclic lactone used clinically to treat nematode infections but also employed by electrophysiologists as a positive allosteric modulator of various ligand-gated ion channels, including homomeric P2X4R, but not other P2X-family receptors (Silberberg et al., 2007). Because ivermectin had no effect on the channel activity of P2X7R homomers, Guo et al. (2007) concluded that P2X4-S341W retains the ivermectin interaction sites of wild-type P2X4 and thereby confers ivermectin sensitivity to heteromeric complexes of P2X4-S341W/P2X7 channels that are gated by the ATP-binding sites on the P2X7 subunits.

Interaction between P2X4R and P2X7R: A Union Presaged by Gene Duplication and Overlapping Patterns of Expression? From a teleological perspective, a specific interaction between P2X7R and P2X4R subunits could be presaged on the basis of several features of both gene products:

Chromosomal Location. The genes encoding human P2X7R and P2X4R are both closely located near the tip of human chromosome 12 at 12q24.31 and are separated by less than 24 kilobase pairs (North, 2002). Likewise, the genes for murine P2X7R and P2X4R are in tandem loci only 26.46 kilobase pairs apart on murine chromosome 5. These tandem chromosomal locations suggest that the P2X7 and P2X4 are related by gene duplication.

Sequence Homology. Based on the sequences of its extracellular loop and transmembrane domains, P2X4R is the P2X family member most closely related to P2X7R, with 48.6% pairwise amino acid identity (for human P2X7R and P2X4R). This contrasts with the 41 to 45% identities between P2X7R and the other P2XR subtypes (North, 2002).

Coexpression in Multiple Nonexcitatory Tissues and Cells. The overlapping expression of P2X4R and P2X7R mRNA, protein, and presumed homomeric channel activity has been documented in multiple tissues and nonexcitatory cell types, including epithelial cells from salivary glands (Tenneti et al., 1998), exocrine pancreas (Hede et al., 1999), and airways (Korngreen et al., 1998; Zsembery et al., 2003),



Fig. 1. Membrane topology and signaling functions of P2X7R homomers, P2X4R homomers, and P2X4R/P2X7R heteromers

myeloid-lineage leukocytes that include macrophages (Guo et al., 2007) and microglial cells (Raouf et al., 2007) and osteoclasts (Korcok et al., 2004). Patch-clamp analysis of ATP-gated inward currents (I_{ATP}) in these cell types has generally indicated biphasic relationships between I_{ATP} and ATP concentration, with one set of currents stimulated by micromolar ATP and a second group of currents triggered in response to millimolar ATP.

Overlapping Roles of P2X7R and P2X4R in Inflammatory Pain Signaling. Using a Freund's complete adjuvant (FCA)-injected paw model of inflammation, Chessel et al. (2005) found that local IL-1β levels in the inflamed paws of P2X7R-null mice were reduced 2.5-fold at 1 day after and 5.4-fold at 7 days after FCA injection, with no global changes in serum IL-1β. Moreover, the hypersensitivity to thermal or mechanical stimuli (i.e., allodynia or inflammatory pain) that characterizes the inflamed paws of control mice was completely absent in the P2X7R-knockout animals. Likewise, Tsuda et al. (2003) used a spinal cord injury model to show that pharmacological or antisense suppression of P2X4R signaling in microglial cells markedly decreased the mechanical allodynia that accompanies this type of nerve injury. Thus, both P2X4R and P2X7R play overlapping roles in inflammatory nociception and have been considered as potential therapeutic targets in this condition.

Interaction between P2X4R and P2X7R: Implications and Questions for Future Study. This newly identified ability of P2X7R to interact with P2X4R has multiple implications regarding current understanding of P2X7R-based functional responses and also generates significant questions for future study.

Regulation of Secondary P2X7R Signaling Responses by P2X4/P2X7 Heteromers? Homomeric P2X7R channels and homomeric P2X4R channels both trigger the common depolarization and Ca^{2+} influx responses that typify all subtypes of ATP-gated ion channels. However, many studies have demonstrated that P2X7R additionally elicits a wide range of secondary signaling responses more typically associated with G protein-coupled receptors than ligand-gated channel receptors (Fig. 1). Activation of these downstream signaling pathways by P2X7R in myeloid or lymphoid leukocytes probably underlies the ability of this receptor to shape the intensity or duration of innate immune and inflammatory responses (Ferrari et al., 2006). Although gating of cation channel function is the most immediate consequence of ATP-induced changes in P2X7R conformation, increasing evidence suggests that the P2X7R also acts as a docking site for multiple intracellular proteins. Kim et al. (2001) used proteomic analysis of anti-P2X7R immunoprecipitates to demonstrate P2X7R association with various signaling and cytoskeletal proteins. Moreover, sustained stimulation of P2X7R additionally induces the flux of molecules $\leq$800 Da through an indirectly regulated nonspecific porin recently identified as pannexin-1 (Pelegrin and Surprenant, 2006). P2X7R also activates the small GTPase Rho that can activate phospholipase D, Rho-effector kinases (ROCKs) and ROCK-dependent membrane blebbing (el-Moatassim and Dubyak, 1992; Verhoef et al., 2003). The massive increase in Ca^{2+} induced by P2X7R elicits a rapid flip of phosphatidylserine to the outer leaflet of the plasma membrane, similar to that observed in apoptotic cells (Mackenzie et al., 2005). The P2X7 receptor is significantly larger (595 amino acids) than all other P2X subtypes because of its much longer intracellular C terminus. This unique C-terminal tail appears to contain the molecular determinants for induction of the various secondary signaling responses, including the pannexin-mediated change in membrane permeability (North, 2002). In contrast, the cytosolic C terminus of P2X4R is the shortest among P2XR subtypes (Fig. 1) such that the juxtaposed intracellular domains of a P2X4R homotrimer are less likely to constitute an effective platform for recruitment of various signaling proteins or interaction with pannexins. However, depending on their stoichiometry, P2X4R/P2X7R heteromers will contain one or two P2X7R-derived C termini, which may be sufficient for recruitment of at least a subset of the downstream signaling proteins that shape the integrated cellular responses to P2X7R stimulation.

Dynamic Regulation of P2X4R/P2X7R Heteromer Copy Number and P2X4R/P2X7R heteromer stoichiometry. The expression of both P2X7R and P2X4R is known to be regulated during proinflammatory activation of monocyte/macrophages (Humphreys and Dubyak, 1998), microglia (Raouf et al., 2007), and endothelial cells (Ramirez and Kunze, 2002; Wilson et al., 2007). P2X7R is strongly expressed in resting macrophages and microglia, whereas P2X4R expression is modest. However, activation of toll-like receptor receptors by lipopolysaccharide or other inflammatory stimuli markedly up-regulates P2X4R but does not alter P2X7R levels (Raouf et al., 2007). Conversely, there is high P2X4R expression (Yamamoto et al., 2006) and little or no P2X7R expression (Beigi et al., 2003) in noninflamed vascular endothelial cells (EC); P2X7R is increased when EC are exposed to inflammatory cytokines (Wilson et al., 2007). These observations suggest that the relative copy numbers of both P2X7R and P2X4R subunits will change in these various cell types at different stages of inflammatory activation. Thus, future studies will need to test how these alterations in P2X7R and P2X4R subunit levels dynamically regulate their relative distribution in P2X7 homomers, P2X4 homomers, and the two possible types of P2X4R/P2X7R heteromeric channels.

Modulation of P2X7-Based Phenotypic Responses in P2X4 Knockout Mice. Finally, a related set of issues pertains to whether certain altered phenotypes observed in P2X7R-knockout mice might actually involve the specific absence of P2X4R/P2X7R heteromers versus P2X7R homomeric channels. These phenotypes include reduced progression of anti-collagen–induced arthritis (Labasi et al., 2002), change in bone density during aging (Ke et al., 2003), and processing of inflammatory pain stimuli (Chessell et al., 2005). The recent availability of several P2X4R knockout mouse lines should facilitate future experiments that test whether the absence of P2X4R recapitulates or additionally modulates these phenotypic changes associated with P2X7R deletion (Sim et al., 2006; Yamamoto et al., 2006).

References

Beigi RD, Kertesy SB, Aquilina G, and Dubyak GR (2003) Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. *Br J Pharmacol* **140:**507–519.

Brown SG, Townsend-Nicholson A, Jacobson KA, Burnstock G, and King BF (2002) Heteromultimeric P2X(1/2) receptors show a novel sensitivity to extracellular pH. *J Pharmacol Exp Ther* **300:**673–680.

Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, et al. (2005) Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. *Pain* **114:**386–396.

Donnelly-Roberts DL, and Jarvis MF (2007) Discovery of P2X7 receptor-selective

antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. *Br J Pharmacol* **151:**571–579.
el-Moatassim C, and Dubyak GR (1992) A novel pathway for the activation of phospholipase D by P2z purinergic receptors in BAC1.2F5 macrophages. *J Biol Chem* **267:**23664–23673.
Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, and Di Virgilio F (2006) The P2X7 receptor: a key player in IL-1 processing and release. *J Immunol* **176:**3877–3883.
Guo C, Masin M, Qureshi OS, and Murrell-Lagnado RD (2007) Evidence for functional P2X4/P2X7 heteromeric receptors. *Mol Pharmacol* **72:**1447–1456.
Hede SE, Amstrup J, Christoffersen BC, and Novak I (1999) Purinoceptors evoke different electrophysiological responses in pancreatic ducts. P2Y inhibits K^+ conductance, and P2X stimulates cation conductance. *J Biol Chem* **274:**31784–31791.
Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, Chandran P, et al. (2006) A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. *J Pharmacol Exp Ther* **319:**1376–1385.
Humphreys BD and Dubyak GR (1998) Modulation of P2X7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. *J Leukoc Biol* **64:**265–273.
Ke HZ, Qi H, Weidema AF, Zhang Q, Panupinthu N, Crawford DT, Grasser WA, Paralkar VM, Li M, Audoly LP, et al. (2003) Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. *Mol Endocrinol* **17:**1356–1367.
Khakh BS and North RA (2006) P2X receptors as cell-surface ATP sensors in health and disease. *Nature* **442:**527–532.
Kim M, Jiang LH, Wilson HL, North RA, and Surprenant A (2001) Proteomic and functional evidence for a P2X7 receptor signalling complex. *EMBO J* **20:**6347–6358.
King BF, Townsend-Nicholson A, Wildman SS, Thomas T, Spyer KM, and Burnstock G (2000) Coexpression of rat P2X2 and P2X6 subunits in *Xenopus* oocytes. *J Neurosci* **20:**4871–4877.
Korcok J, Raimundo LN, Ke HZ, Sims SM, and Dixon SJ (2004) Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts. *J Bone Miner Res* **19:**642–651.
Korngreen A, Ma W, Priel Z, and Silberberg SD (1998) Extracellular ATP directly gates a cation-selective channel in rabbit airway ciliated epithelial cells. *J Physiol* **508:**703–720.
Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, and Gabel CA (2002) Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. *J Immunol* **168:**6436–6445.
Lê KT, Babinski K, and Seguela P (1998) Central P2X4 and P2X6 channel subunits coassemble into a novel heteromeric ATP receptor. *J Neurosci* **18:**7152–7159.
Lewis C, Neidhart S, Holy C, North RA, Buell G, and Surprenant A (1995) Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. *Nature* **377:**432–435.
Mackenzie AB, Young MT, Adinolfi E, and Surprenant A (2005) Pseudoapoptosis induced by brief activation of ATP-gated P2X7 receptors. *J Biol Chem* **280:**33968–33976.
Nicke A, Kerschensteiner D, and Soto F (2005) Biochemical and functional evidence for heteromeric assembly of P2X1 and P2X4 subunits. *J Neurochem* **92:**925–933.
North RA (2002) Molecular physiology of P2X receptors. *Physiol Rev* **82:**1013–1067.
North RA and Surprenant A (2000) Pharmacology of cloned P2X receptors. *Annu Rev Pharmacol Toxicol* **40:**563–580.
Pelegrin P and Surprenant A (2006) Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. *EMBO J* **25:**5071–5082.
Ramirez AN and Kunze DL (2002) P2X purinergic receptor channel expression and function in bovine aortic endothelium. *Am J Physiol Heart Circ Physiol* **282:**H2106–H2116.
Raouf R, Chabot-Dore AJ, Ase AR, Blais D, and Seguela P (2007) Differential regulation of microglial P2X4 and P2X7 ATP receptors following LPS-induced activation. *Neuropharmacology* **53:**496–504.
Silberberg SD, Chang TH, and Swartz KJ (2005) Secondary structure and gating rearrangements of transmembrane segments in rat P2X4 receptor channels. *J Gen Physiol* **125:**347–359.
Silberberg SD, Li M, and Swartz KJ (2007) Ivermectin Interaction with transmembrane helices reveals widespread rearrangements during opening of P2X receptor channels. *Neuron* **54:**263–274.
Sim JA, Chaumont S, Jo J, Ulmann L, Young MT, Cho K, Buell G, North RA, and Rassendren F (2006) Altered hippocampal synaptic potentiation in P2X4 knockout mice. *J Neurosci* **26:**9006–9009.
Tenneti L, Gibbons SJ, and Talamo BR (1998) Expression and trans-synaptic regulation of P2x4 and P2z receptors for extracellular ATP in parotid acinar cells. Effects of parasympathetic denervation. *J Biol Chem* **273:**26799–26808.
Torres GE, Egan TM, and Voigt MM (1999) Hetero-oligomeric assembly of P2X receptor subunits. Specificities exist with regard to possible partners. *J Biol Chem* **274:**6653–6659.
Torres GE, Haines WR, Egan TM, and Voigt MM (1998) Co-expression of P2X1 and P2X5 receptor subunits reveals a novel ATP-gated ion channel. *Mol Pharmacol* **54:**989–993.
Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, and Inoue K (2003) P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. *Nature* **424:**778–783.
Verhoef PA, Estacion M, Schilling W, and Dubyak GR (2003) P2X7 receptor-dependent blebbing and the activation of Rho-effector kinases, caspases, and IL-1 beta release. *J Immunol* **170:**5728–5738.
Wilson HL, Varcoe RW, Stokes L, Holland KL, Francis SE, Dower SK, Surprenant A, and Crossman DC (2007) P2X receptor characterization and IL-1/IL-1Ra release from human endothelial cells. *Br J Pharmacol* **151:**115–127.
Yamamoto K, Sokabe T, Matsumoto T, Yoshimura K, Shibata M, Ohura N, Fukuda T, Sato T, Sekine K, Kato S, et al. (2006) Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. *Nat Med* **12:**133–137.
Zsembery A, Boyce AT, Liang L, Peti-Peterdi J, Bell PD, and Schwiebert EM (2003) Sustained calcium entry through P2X nucleotide receptor channels in human airway epithelial cells. *J Biol Chem* **278:**13398–13408.

Address correspondence to: George R. Dubyak, Department of Physiology and Biophysics, Case Western Reserve University, School of Medicine, Cleveland, OH 44106. E-mail: george.dubyak@case.edu